NIBEC Co. vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how NIBEC Co. (138610) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 11, 2026.
As of Aug 11, 2026, Fair Value Calculator sees NIBEC Co. as the less overvalued of the two: NIBEC Co. trades at KRW 17,100 versus a fair value of KRW 11,964 (-30%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
NIBEC Co.
138610.KQ · KRW · Health Care
-30%
upside to fair value
overvalued
PriceKRW 17,100
Fair ValueKRW 11,964
Quality62/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-44%
upside to fair value
overvalued
Price$496
Fair Value$279
Quality79/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
NIBEC Co.Vertex Pharmaceuticals
Valuation
—P/E (TTM)28.8×
—P/S (TTM)10.06×
—P/B6.59×
—EV/EBITDA23.8×
—PEG1.72×
Profitability
23%Net margin36%
3%Operating margin38%
19%Return on equity24%
7%Return on assets12%
Growth
-7%Revenue growth (YoY)8%
14.7%Avg. growth/yr (3Y)10.6%
38.8%Avg. growth/yr (5Y)14.2%
Balance & size
0.02×Debt / equity0.03×
$111MMarket cap$123B
expensiveGrowth qualityhealthy
Vertex Pharmaceuticals leads: 3 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
NIBEC Co.of which business quality 60 · market factors 17Vertex Pharmaceuticalsof which business quality 77 · market factors 65
ProfitabilityMargins and returns on capital today
50
72
Quality GrowthAre margins and returns improving?
100
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
61
58
Low VolatilityCalm price path (market factor)
49
86
MomentumPrice trend over the last 3–12 months (market factor)
3
54
52W MomentumDistance to the 52-week high (market factor)
6
59
Net IssuanceBuybacks instead of dilution
40
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
NIBEC Co.
DCF ModelsKRW 12,016
Earnings-BasedKRW 12,430
MultiplesKRW 8,294
Asset-BasedKRW 2,701
Growth DCFKRW 6,520
Economic ProfitKRW 6,941
Growth EarningsKRW 16,968
23 of 24 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692
18 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
NIBEC Co.
Bear KRW 6,353Fair Value KRW 11,964Bull KRW 15,068
KRW 17,100 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$496 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
NIBEC Co. · Health Care
Quality score62 · above median
Fair value upside-30% · below median
Vertex Pharmaceuticals · Health Care
Quality score79 · Top 25%
Fair value upside-44% · below median
Bottom line
As of Aug 11, 2026, Fair Value Calculator sees NIBEC Co. as the less overvalued of the two: NIBEC Co. trades at KRW 17,100 versus a fair value of KRW 11,964 (-30%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Vertex Pharmaceuticals has the higher quality score (79/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
